Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)

This study is testing whether adding an immunotherapy drug called cadonilimab to standard chemotherapy — before and after surgery — can improve outcomes for people with a type of esophageal (food pipe) cancer called squamous cell carcinoma that can be surgically removed. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with esophageal squamous cell carcinoma that doctors believe can be surgically removed - Your heart, lungs, liver, and kidneys are functioning well enough to tolerate treatment - You are well enough to carry out daily activities (not severely debilitated) **You may NOT be eligible if...** - Your cancer has spread to distant parts of the body or cannot be surgically removed - You have had another cancer in the past 5 years - You have an active autoimmune disease (where your immune system attacks your own body) - You have active hepatitis B, tuberculosis, HIV, or other serious infections - You are pregnant or breastfeeding - You have had a heart attack, unstable heart disease, or serious heart failure in the past year - You have previously received chemotherapy or immunotherapy for this cancer Talk to your doctor to see if this trial is right for you.